AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial

Biopharmaceutical company AbbVie (ABBV) in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced detailed results from a Phase 2b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone acetate) compared to placebo.

from RTT - Biotech http://ift.tt/2oIZLOM
via IFTTT